Physician profile
Andrew King
NPI 1528468527
$2,061.57
in general payments reported to CMS, 2019-2025
20 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $284 · 2021: $446 · 2022: $135 · 2023: $119 · 2024: $55.64 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $354.81 | 2019-2021 | |
| Novo Nordisk INC | $341.49 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $308.65 | 2019-2025 | Euflexxa |
| Astrazeneca Pharmaceuticals Lp | $235.36 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.67 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $91.93 | 2022-2024 | Zilretta, Iovera |
| Bioventus LLC | $89.73 | 2022-2025 | Durolane, Exogen Ultrasound Bone Healing System |
| Lilly USA, LLC | $74.90 | 2020-2023 | Mounjaro |
| Amgen INC. | $62.54 | 2025 | |
| Pylant Medical | $54.88 | 2023-2025 | |
| Pfizer INC. | $54.62 | 2021-2025 | |
| Abbvie INC. | $42.80 | 2021 | |
| Depuy Synthes Sales INC. | $39.82 | 2025 | Orthovisc, Monovisc |
| Glaxosmithkline, LLC. | $33.20 | 2019-2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $28.79 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $21.44 | 2025 | |
| Abbott Laboratories | $21.30 | 2023 | Octrode |
| Allergan, INC. | $15.66 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.42 | 2020 | |
| Corium, LLC | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.